Page last updated: 2024-12-09

nsc 4347

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NSC 4347: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
PipergenusA plant genus of the family PIPERACEAE that includes species used for spicy and stimulating qualities.[MeSH]PiperaceaeA family of flowering plants in the order Piperales best known for the black pepper widely used in SPICES, and for KAVA and Betel used for neuroactive properties.[MeSH]

Cross-References

ID SourceID
PubMed CID657306
CHEMBL ID1401367
SCHEMBL ID249587
MeSH IDM0509320

Synonyms (100)

Synonym
MLS001148441
1-ethyl-3-{[hydroxy(diphenyl)acetyl]oxy}-1-methylpiperidinium bromide
n-ethyl-3-piperidylbenzilate methobromide
piptal, tablet
qpb ,
125-51-9
piperidinium, bromide, benzilate
piptil
benzilic acid, ester with 1-ethyl-3-hydroxy-1-methylpiperidinium bromide
pipenzolate methobromide
1-ethyl-3-piperidyl benzilate methylbromide
nsc-4347
benzilic acid, 1-ethyl-3-piperidyl ester methylbromide
piptalake
jb 323
pipenzolate methyl bromide
1-ethyl-3-hydroxy-1-methyl-piperidinium bromide, benzilic acid ester
nsc4347
1-ethyl-3-hydroxy-1-methyl-piperidinium bromide benzilate
pipenzolate bromide
pipenzolatemethyl bromide
piper
piptal
wln: t6ktj a2 a1 covxqr & r & q & e
jb-323
nepb br
PRESTWICK_159
cas-125-51-9
pipenzolate bromide (inn)
D07084
piperidinium, 1-ethyl-3-((hydroxydiphenylacetyl)oxy)-1-methyl-, bromide
einecs 204-741-2
piptal (tablet)
pipenzolate methylbromide
pipenzolate bromide [inn:ban]
bromuro de pipenzolato [inn-spanish]
piperidinium, 1-ethyl-3-hydroxy-1-methyl-, bromide, benzilate
pipenzolati bromidum [inn-latin]
bromure de pipenzolate [inn-french]
pipenzolato bromuro [dcit]
nsc 4347
NCGC00094991-02
NCGC00094991-01
MLS000069572 ,
smr000058823
SPECTRUM1503053
NCGC00094991-03
NCGC00094991-04
MLS002222177
HMS501P20
HMS1570G22
HMS1922A21
pipenzolone bromide
CHEMBL1401367
HMS2097G22
pharmakon1600-01503053
nsc-758221
nsc758221
dtxsid2023480 ,
dtxcid503480
tox21_111378
HMS2232D11
CCG-39184
jpx41dus2b ,
bromuro de pipenzolato
pipenzolati bromidum
bromure de pipenzolate
pipenzolato bromuro
unii-jpx41dus2b
HMS3370K12
pipenzolate bromide [mart.]
piperidinium, 1-ethyl-3-((2-hydroxy-2,2-diphenylacetyl)oxy)-1-methyl-, bromide (1:1)
pipenzolate bromide [inn]
pipenzolate bromide [mi]
1-ethyl-3-((hydroxydiphenylacetyl)oxy)-1-methylpiperidinium bromide
pipenzolate bromide [who-dd]
n-ethyl-3-piperidyl benzilate methobromide
SCHEMBL249587
AKOS022180522
NCGC00018203-06
tox21_111378_1
REGID_FOR_CID_657306
pipenzolate (bromide)
HY-B0953A
OPERA_ID_154
SR-01000003111-4
sr-01000003111
SR-01000003111-3
HMS3714G22
(1-ethyl-1-methylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate;bromide
SW196470-3
FT-0715349
SY250231
mfcd00079275
1-ethyl-3-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-piperidinium bromide
1-ethyl-3-(2-hydroxy-2,2-diphenylacetoxy)-1-methylpiperidin-1-ium bromide
1-ethyl-3-(2-hydroxy-2,2-diphenylacetoxy)-1-methylpiperidinium bromide
AC8884
Q27281629
piperidinium, 1-ethyl-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-, bromide (1:1)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Because this compound shows interesting biological activities, it is extremely important to evaluate its possible genotoxic activity to allow its safe use in humans."( Genotoxic effects of (-)-cubebin in somatic cells of mice.
de Souza, GH; Maistro, EL; Natel, AV; Perazzo, FF, 2011
)
0.37
"Piper umbellatum did not appear to be toxic in the in vitro (IC50>200 µg/mL) cytotoxicity test."( Evaluation of acute toxicity, antibacterial activity, and mode of action of the hydroethanolic extract of Piper umbellatum L.
da Costa Alvim, T; da Silva, IF; de Oliveira Martins, DT; de Oliveira, RG; Donizeti Ascêncio, S; Mendes Soares, I, 2014
)
0.4
" This situation imposes an urgent development of more selective and less toxic agents."( Cytotoxic effects of dillapiole on MDA-MB-231 cells involve the induction of apoptosis through the mitochondrial pathway by inducing an oxidative stress while altering the cytoskeleton network.
Auada, AV; Câmara, DA; Costa, AS; Damião, MC; de Azevedo, RA; de-Sá-Júnior, PL; Ferreira, AK; Figueiredo, CR; Kerkis, I; Lebrun, I; Magri, FM; Massaoka, MH; Matsuo, AL; Parise Filho, R; Pasqualoto, KF; Tavares, MT, 2014
)
0.4
" Piperlonguminine was the more effective amide, showing toxic activity with LD50 of approximately 12 microg/ml against the larvae of Ae."( Cytotoxicity of piperamides towards Aedes aegypti (Diptera: Culicidae).
Ferreira, B; Guimarães, A; Kato, M; Maleck, M; Mallet, J, 2014
)
0.4
" Its control is currently hampered by the lack of a macrofilaricidal drug and by severe adverse events observed when the lone recommended microfilaricide, ivermectin is administered to individuals co-infected with Loa loa."( Filaricidal activities on Onchocerca ochengi and Loa loa, toxicity and phytochemical screening of extracts of Tragia benthami and Piper umbellatum.
Azantsa, BK; Babiaka, SB; Cho-Ngwa, F; Manfo, FP; Mbah, JA; Monya, E; Samje, M, 2016
)
0.43
" Active extracts were generally more toxic to the worms than to cells and showed no acute toxicity to Balb/c mice."( Filaricidal activities on Onchocerca ochengi and Loa loa, toxicity and phytochemical screening of extracts of Tragia benthami and Piper umbellatum.
Azantsa, BK; Babiaka, SB; Cho-Ngwa, F; Manfo, FP; Mbah, JA; Monya, E; Samje, M, 2016
)
0.43
" Tannins values obtained were not adverse to their consumption."( [Concentrations of alkaloids, cyanogenic glycosides, polyphenols and saponins in selected medicinal plants from Ecuador and their relationship with acute toxicity against Artemia salina].
D'Armas, H; Jaramillo Espinoza, A; Jaramillo Jaramillo, C; Rojas de Astudillo, L; Troccoli, L, 2016
)
0.43
" General behaviour, adverse effects, and mortality were determined."( Chemical characterisation of Piper amalago (Piperaceae) essential oil by comprehensive two-dimensional gas chromatography coupled with rapid-scanning quadrupole mass spectrometry (GC×GC/qMS) and their antilithiasic activity and acute toxicity.
Caramão, EB; Cardoso, CAL; de Barros, ME; Dos Santos, AL; Jacques, RA; Krause, LC; Lima, DBM; Mota, JS; Novaes, ADS; Polidoro, ADS, 2018
)
0.48
" There were no adverse effects observed in the rats, and body weights and food intakes were not significantly different between the control and the kawakawa treated animals."( Composition and safety evaluation of tea from New Zealand kawakawa (Piper excelsum).
Butts, CA; Harvey, D; Hedderley, DI; Joyce, NI; Martell, S; Paturi, G; van Klink, JW, 2019
)
0.51
" However, few studies have focused on its adverse effects, compromising its safe use."( Evaluation of the safety of ethanolic extract from Piper amalago L. (Piperaceae) leaves in vivo: Subacute toxicity and genotoxicity studies.
Arena, AC; Casali Reis, AC; da Silva Moreira, S; da Silva Mota, J; Fraga, TL; Jorge, BC; Kassuya, CAL; Oliveira, RJ; Santos Radai, JA; Stein, J, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacodynamic study was carried out to evaluate the effect of Trikatu on the anti-inflammatory activity of diclofenac sodium using carragenin-induced rat paw edema model."( Pharmacokinetic and pharmacodynamic studies on interaction of "Trikatu" with diclofenac sodium.
D'Mello, PM; Lala, LG; Naik, SR, 2004
)
0.32
"The pharmacokinetic profile of orally administered oxytetracycline (10 mg/kg body weight) was studied 7 days post oral treatment of Piper longum (15 mg equivalent/kg) in White Leghorn hens (2-2."( Alteration of pharmacokinetics of oxytetracycline following oral administration of Piper longum in hens.
Singh, M; Srivastava, AK; Telang, RS; Varshneya, C, 2005
)
0.33
" The mean plasma drug concentrations at different time points and the pharmacokinetic parameters before and after piperine administration were compared by Student's t-test."( Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy.
Hota, D; Kharbanda, P; Pandhi, P; Pattanaik, S; Prabhakar, S, 2006
)
0.33
" The apparent volume of distribution based on the total area under the plasma drug concentration curve [(Vd(area)] and the apparent volume of distribution based on the zero time plasma concentration intercept of the elimination phase [Vd(B)] were significantly higher in trikatu treated animals indicating a better penetration of the drug."( Effect of trikatu pretreatment on the pharmacokinetics of pefloxacin administered orally in mountain Gaddi goats.
Dama, MS; Dardi, MS; Katoch, VC; Varshneya, C, 2008
)
0.35
" The pharmacokinetic parameters were compared by Students t-test."( Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients.
Hota, D; Kharbanda, P; Pandhi, P; Pattanaik, S; Prabhakar, S, 2009
)
0.35
" This study examined the pharmacokinetic characteristics of laetispicine in plasma and brain distribution in rats by a simple sensitive HPLC-UV method."( Pharmacokinetics of laetispicine and its brain distribution in rats.
Pan, SL; Wang, Y; Xie, H, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" Nevertheless, the effect of such drug combination usage on the in vivo exposure of PIP has not been investigated due to lack of assay for the simultaneous determination of PIP and other drugs such as DOX."( Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats.
Chow, MSS; Lam, CWK; Li, C; Ren, T; Wang, Q; Zhang, Y; Zuo, Z, 2016
)
0.43
" The results of the systematic review showed that piperine has promising anti-TB activity, mainly when combined with antimicrobials, and plays an important role as an EP inhibitor."( Promising Antituberculosis Activity of Piperine Combined with Antimicrobials: A Systematic Review.
Almeida, AL; Barros, ILE; Caleffi-Ferracioli, KR; Campanerut-Sá, PAZ; Canezin, PH; Cardoso, RF; Hegeto, LA; Nakamura de Vasconcelos, SS; Perez de Souza, J; Scodro, RBL; Siqueira, VLD; Teixeira, JJV,
)
0.13

Bioavailability

ExcerptReferenceRelevance
""Trikatu"-an Ayurvedic formulation comprising of a 1:1:1 ratio of dried fruits of Piper nigrum, Piper longum and dried rhizomes of Zingiber officinale is widely used to enhance the bioavailability of drugs, like vasicine, indomethacin, etc."( Pharmacokinetic and pharmacodynamic studies on interaction of "Trikatu" with diclofenac sodium.
D'Mello, PM; Lala, LG; Naik, SR, 2004
)
0.32
"Piperine, the active principle of Piper longum, Piper nigrum and Zingiber officinalis, has been reported to enhance the oral bioavailability of phenytoin in human volunteers."( Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy.
Hota, D; Kharbanda, P; Pandhi, P; Pattanaik, S; Prabhakar, S, 2006
)
0.33
" Piperine could significantly enhance the oral bioavailability of carbamazepine, possibly by decreasing the elimination and/or by increasing its absorption."( Pharmacokinetic interaction of single dose of piperine with steady-state carbamazepine in epilepsy patients.
Hota, D; Kharbanda, P; Pandhi, P; Pattanaik, S; Prabhakar, S, 2009
)
0.35
" This compound is selectively cytotoxic against cancer cells by induction of oxidative stress, induces genotoxicity, as an alternative strategy to killing tumor cells, has excellent oral bioavailability in mice, inhibits tumor growth in mice, and presents only weak systemic toxicity."( Overview of the therapeutic potential of piplartine (piperlongumine).
Bezerra, DP; Costa-Lotufo, LV; de Moraes, MO; Pessoa, C; Saker-Neto, N; Silveira, ER, 2013
)
0.39
" The present study aimed to investigate the efficacy of short-term supplementation with curcuminoids (co-administered with piperine to enhance the bioavailability of curcuminoids) in alleviating systemic oxidative stress and clinical symptoms, and improvement of health-related quality of life (HRQoL) in subjects suffering from chronic pulmonary complications due to SM exposure who are receiving standard respiratory treatments."( Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial.
Ghanei, M; Hajhashemi, A; Panahi, Y; Sahebkar, A, 2016
)
0.43
"We combine quantum chemical and molecular docking techniques to provide new insights into how piperine molecule in various forms of pepper enhances bioavailability of a number of drugs including curcumin in turmeric for which it increases its bioavailability by a 20-fold."( Quantum Chemical and Docking Insights into Bioavailability Enhancement of Curcumin by Piperine in Pepper.
Balasubramanian, K; Das, S; Patil, VM, 2016
)
0.43
" Besides, the reported pharmacokinetics of PIP varied a lot without appropriate bioavailability determined from the same dose."( Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats.
Chow, MSS; Lam, CWK; Li, C; Ren, T; Wang, Q; Zhang, Y; Zuo, Z, 2016
)
0.43
" These results suggest that MST may be effective in enhancing the bioavailability of ginkgolide A in GBE."( Mixing Ginkgo biloba Extract with Sesame Extract and Turmeric Oil Increases Bioavailability of Ginkgolide A in Mice Brain.
Ayaki, I; Iwamoto, K; Kawamoto, H; Matsumura, S; Moriyama, T; Takeshita, F; Zaima, N, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Methods: We report a pilot three-arm randomized crossover study to assess the bioavailability of kawakawa tea (BOKA-T) in six male participants with each arm having an acute intervention of kawakawa tea (4 g/250 mL water; 1 g/250 mL water; water) and a follow-up two-arm randomized crossover study to assess the impact of acute kawakawa tea ingestion on postprandial glucose metabolism in healthy human volunteers (TOAST) (4 g/250 mL water; and water; n = 30 (15 male and 15 female))."( Acute Effects of Kawakawa (
Foster, M; Jayaprakash, R; Miles-Chan, JL; Mithen, R; Pook, C; Ramzan, F, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
"2%) in relation to cubebin (57%) and indomethacin (77%) in the carrageenin-induced paw edema in rats, but on the other hand it was more effective (80%) than (-)-cubebin (41%) in inhibiting acetic acid-induced writhing in mice, producing dose-response correlation with doses of 10, 20 and 40 mg/kg, respectively."( Analgesic and anti-inflammatory activities of (-)-o benzyl cubebin, a (-)-cubebin derivative, obtained by partial synthesis.
Bastos, JK; Carvalho, JC; Coimbra, Hdos S; Cunha, WR; da Silva, R; de Souza, GH; de Souza, VA; Donate, PM; Pereira, AC; Royo, Vde A; Silva, ML, 2004
)
0.32
" Dose-response curves were also constructed for pre-incubation of vascular rings with Nω-nitro-L-arginine methyl ester (L-NAME) (a non-specific nitric oxide synthase inhibitor), indomethacin (an unspecific cyclooxygenase inhibitor), and 1H-[1,2,4] oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) (a guanylyl cyclase inhibitor)."( The lignan (-)-cubebin inhibits vascular contraction and induces relaxation via nitric oxide activation in isolated rat aorta.
Andrade E Silva, ML; Bastos, JK; Carvalho, MT; Celotto, AC; Cunha, WR; Evora, PR; Rezende, KC, 2013
)
0.39
"During the short term study the aqueous extract at a dosage of 200 mg/kg."( Antidiabetic and antihyperlipidemic activity of Piper longum root aqueous extract in STZ induced diabetic rats.
Kasetti, RB; Kumar, MV; Nabi, SA; Rao, CA; Sirasanagandla, S; Tilak, TK, 2013
)
0.39
" However, studies with better separation of the types of tobacco and the ways in which it is used, and studies with sufficient power to quantify dose-response relationships are still needed."( Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific.
Gupta, B; Johnson, NW, 2014
)
0.4
" The emergence of fluke resistance due to over or under dosing of fasciolides as well as environmental damage produced by the chemicals eliminated in field have stimulated the need for alternative methods to control Fasciola hepatica."( In vitro antihelmintic effect of fifteen tropical plant extracts on excysted flukes of Fasciola hepatica.
Alonso-Díaz, MÁ; Alvarez-Mercado, JM; Avila-Acevedo, JG; García-Bores, AM; Ibarra-Velarde, F; Vera-Montenegro, Y, 2015
)
0.42
"The results suggest that EAE-P is beneficial to the behavioral outcome of the CUMS model animals, and decreased amounts of inflammatory cytokine IL-6 contributed to the antidepressant-like activation of EAE-P in every dosage group (15, 30, 60 mg/kg)."( The effect of Piper laetispicum extract (EAE-P) during chronic unpredictable mild stress based on interrelationship of inflammatory cytokines, apoptosis cytokines and neurotrophin in the hippocampus.
Chen, J; Jin, D; Kang, Y; Liu, H; Liu, J; Pan, S; Shen, H; Shi, X; Xie, H; Yan, M, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.73080.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency3.26430.000811.382244.6684AID686979
farnesoid X nuclear receptorHomo sapiens (human)Potency21.13000.375827.485161.6524AID743220
cytochrome P450 2D6Homo sapiens (human)Potency2.75400.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency33.48890.023723.228263.5986AID743222
ras-related protein Rab-9AHomo sapiens (human)Potency3.98110.00022.621531.4954AID485297
gemininHomo sapiens (human)Potency0.22390.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.64240.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (61)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (821)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (1.22)18.7374
1990's0 (0.00)18.2507
2000's198 (24.12)29.6817
2010's451 (54.93)24.3611
2020's162 (19.73)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (1.53%)5.53%
Reviews43 (5.06%)6.00%
Case Studies2 (0.24%)4.05%
Observational1 (0.12%)0.25%
Other790 (93.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]